HK Stock Market Move | ASCLETIS-B(01672) rose more than 6% in the afternoon. The first dose of ASC50 for the treatment of psoriasis in the United States has completed the first phase I clinical trial for participants.

ASCLETIS-B (01672) rose more than 6% in the afternoon, rising 4.82% as of the release of this report to 9.35 Hong Kong dollars, with a transaction volume of 32.9579 million Hong Kong dollars. In terms of news, GeLi Pharmaceutical announced that the US Phase I clinical trial of ASC50, an orally administered small molecule interleukin-17 (IL-17) targeted inhibitor developed independently by GeLi, for the treatment of psoriasis has completed dosing of the first batch of healthy subjects. The trial aims to evaluate the safety, tolerability, and preliminary efficacy of ASC50. Preclinical data shows that ASC50 is expected to become the best daily oral medication for the treatment of psoriasis in its class. It is worth noting that GeLi Pharmaceutical will report early research data on the orally administered small molecule GLP-1 receptor (GLP-1R) agonist ASC30 and the fat-targeted, weight-loss without muscle loss candidate drug ASC47 in poster format at the 85th Annual Scientific Meeting of the American Diabetes Association (ADA) in Chicago, USA. It is reported that the 85th ADA Annual Scientific Meeting will be held in Chicago, USA from June 20 to 23 this year.